U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Reuters3d
Regulatory News | Today's Latest Stories | Reuters
ResMed beats quarterly profit estimates on demand for sleep disorder devices Healthcare & Pharmaceuticalscategory ... next-generation obesity drug CagriSema on Feb. 10 to test its long-term ...
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
IT INTELLIGENT TREATMENT UNVEILS SOMACELL™ AT NYC LAUNCH EVENT WITH PAGE SIX
New York-based medical aesthetic clinic IT Intelligent Treatment unveiled SomaCell™, an industry-disrupting innovation in non ...
Yahoo Finance5d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...
Bloomberg L.P.5d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December.
Nasdaq3d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial success ...
Pharmaceutical Technology5d
Top 20 biopharma companies’ market caps rise 1.7% over 2024 amid policy
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...
Business Insider3d
The Schall Law Firm Invites Shareholders With Losses To Lead A Securities Fraud Case Against Novo Nordisk A/S
Novo issued a press release on December 20, 2024, announcing the disappointing results of its "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." ...
Business Insider3d
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...
Morningstar5d
Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...